AstraZeneca - International Pharmaceutical Industry

News

UK study shows mixing Pfizer and AstraZeneca COVID-19 vaccines with Moderna elicits better immune response

Results show support in favour of heterologous dosing which may help to advance vaccination programmes in poorer countries. A British study mixing COVID-19 vaccin...

7 December 2021 News AstraZeneca | COVID-19 vaccines

Continue Reading →

News

Next virus could be more lethal than COVID-19, warns Oxford vaccine creator

With the emergence of the new Omicron variant bringing into question the effectiveness of current vaccines, scientists caution that viruses will continue to evolve. ...

7 December 2021 News AstraZeneca | COVID-19 vaccine

Continue Reading →

News

NICE recommends Tagrisso for patients with early-stage lung cancer

Following a positive final recommendation from the National Institute for Health and Care Excellence (NICE), AstraZeneca’s Tagrisso (osimertinib) is now available as...

1 December 2021 News AstraZeneca | lung cancer

Continue Reading →

News

AZ announces US fast track designation for IL-5 inhibitor Fasenra

AstraZeneca’s IL-5 inhibitor Fasenra (benralizumab) has received a fast-track designation from the US Food and Drug Administration for the treatment of eosinoph...

9 November 2021 News AstraZeneca | benralizumab

Continue Reading →

News

Global vaccine trade surpasses $42 billion

According to a new report published by IndexBox, in the first half of 2021, global vaccine exports were valued at $42.5 billion, a record high over the last decade. ...

3 November 2021 News AstraZeneca | COVID

Continue Reading →

News

AZ to transfer certain drug rights to Covis Pharma for $270m

AstraZeneca has announced it will transfer global rights to Eklira (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) to Covis Pharma Group in a $270m ...

2 November 2021 News AstraZeneca | chronic obstructive pulmonary disease

Continue Reading →

News

AstraZeneca’s long-acting antibody combination treats and prevents COVID-19

Positive high-level results from the TACKLE Phase III COVID-19 treatment trial have shown that AstraZeneca’s AZD7442, a long-acting antibody (LAAB) combination, achi...

13 October 2021 News antibody | AstraZeneca

Continue Reading →

News

AstraZeneca invests in Imperial College spin-off VaxEquity

AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialisation of the proprietary self-amplifying RNA (saRNA...

29 September 2021 News AstraZeneca | Imperial College

Continue Reading →

News

Positive Phase III results for Lynparza plus abiraterone in metastatic prostate cancer

Positive high-level results from the PROpel Phase III trial have shown that AstraZeneca and MSD’s Lynparza (olaparib), in combination with abiraterone, dem...

29 September 2021 News AstraZeneca | homologous recombination repair

Continue Reading →

News

New tezepelumab data shows improvements for severe asthma subgroup

AstraZeneca and Amgen’s thymic stromal lymphopoietin (TSLP) blocker tezepelumab has demonstrated new improvements for patients with severe asthma and comorbid nasal ...

8 September 2021 News amgen | AstraZeneca

Continue Reading →